Mortality in systemic vasculitis: A systematic review

Clinical and Experimental Rheumatology

Volumn 26, Issue 5 SUPPL. 51, 2008, Pages

  Phillip, Rhodri ^a   Luqmani, Raashid ^a,b  

^a NUFFIELD ORTHOPAEDIC CENTRE   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

ANCA; Giant cell arteritis; Microscopic polyangiitis; Survival; Wegener's granulomatosis

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; IMMUNOGLOBULIN; NEUTROPHIL CYTOPLASMIC ANTIBODY;

AGING; ANAPHYLACTOID PURPURA; AORTA ARCH SYNDROME; ATTRIBUTABLE RISK; BLADDER CANCER; CARDIOVASCULAR DISEASE; CAUSAL ATTRIBUTION; CAUSE OF DEATH; CHURG STRAUSS SYNDROME; CLINICAL ASSESSMENT TOOL; COMORBIDITY; CORONARY ARTERY DISEASE; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG RESPONSE; GIANT CELL ARTERITIS; HIGH RISK PATIENT; HUMAN; INFECTION; KIDNEY DISEASE; LONG TERM CARE; MICROSCOPIC POLYANGIITIS; MORTALITY; MUCOCUTANEOUS LYMPH NODE SYNDROME; MULTIPLE ORGAN FAILURE; ONSET AGE; OVERALL SURVIVAL; POLYARTERITIS NODOSA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; RISK REDUCTION; SINGLE DRUG DOSE; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; SYSTEMIC VASCULITIS; TREATMENT DURATION; WEGENER GRANULOMATOSIS;

ADULT; AGE FACTORS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; CAUSE OF DEATH; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; MULTIPLE ORGAN FAILURE; RISK; SEVERITY OF ILLNESS INDEX; SEX FACTORS; VASCULITIS;

EID: 55349086542     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (91)

1. CARRINGTON CB, LIEBOW A: Limited forms of angiitis and granulomatosis of Wegener's type. Am J Med 1996; 41: 497-527.
2. JAYNE D, RASMUSSEN N, ANDRASSY et al.: EUROPEAN VASCULITIS STUDY GROUP: A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. New Engl J Med 2003; 349: 36-44.
3. HOFFMAN GS, KERR GS, LEAVITT RY et al.: Wegener's granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116: 488-98.
4. GUILLEVIN L, COHEN P, GAYRAUD M, LHOTE F, JARROUSSE B. CASASSUS P: Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999; 78: 26-37.
5. GUILLEVIN L, DURAND-GASSELIN B, CEVALLOS R et al.: Microscopic polyangiitis. Clinical and laboratory findings in eighty-five patients. Arthritis Rheum 1999; 42: 421-30.
6. AASARØD. K, IVERSEN, B, HAMMERSTROM, J, BOSTAD, L, VATTEN L, JØRSTAD S: Wegener's granulomatosis: clinical course in 108 patients with renal involvement. Nephrol Dial Transplant 2000; 15: 611-8.
7. BLIGNY D, MAHR A, LE TOUMELIN P, MOUTHON, L, GUILLEVIN L: Predicting mortality in systemic Wegener's granulomatosis: a survival analysis based on 93 patients. Arthritis Rheum 2004; 51: 83-91.
8. BOOMSMA MM, BIJL M, STEGEMAN CA, KALLENBERG CG, HOFFMAN GS, TERVAERT JW: Patients' perceptions of the effects of systemic lupus erythematosus on health, function, income, and interpersonal relationships: a comparison with Wegener's granulomatosis. Arthritis Rheum 2004; 47: 196-201.
9. METZLER C, HELLMICH B, GAUSE A, GROSS WL, DE GROOT, K: Churg Strauss syndrome-successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment. Clin Exp Rheumatol 2004; 22 (Suppl. 36): S52-61.
10. FAHEY J, LEONARD E, CHURG J, GODMAN GC: Wegener's granulomatosis. Am J Med 1954; 17: 168-79.
11. KOLDINGSNES W, NOSSENT H: Predictors of survival and organ damage in Wegener's granulomatosis. Rheumatology 2002; 41: 572-81.
12. MAHR A, GIRARD T, AGHER R, GUILLEVIN L: Analysis of factors predictive of survival based on 49 patients with systemic Wegener's granulomatosis and prospective followup. Rheumatology 2001; 40: 492-8.
13. PAVONE L, GRASSELLI C, CHIERICI E et al.: Outcome and prognostic factors during the course of primary small-vessel vasculitis. J Rheumatol 2006; 33: 1299-306.
14. REINHOLD-KELLER E, BEUGE N, LATZA U et al.: An interdisciplinary approach to the care of patients with Wegener's granulomatosis. Arthritis Rheum 2000; 43: 1021-32.
15. LANE SE, WATTS RA, SHEPSTONE L, SCOTT DGI: Primary systemic vasculitis: clinical features and mortality. Q J Med 2005; 98: 97-111.
16. LUQMANI RA, BACON PA, BEAMAN M et al.: Classical versus non-renal Wegener's granulomatosis. Q J Med 1994; 87: 161-7.
17. WEIDNER S, GEUSS S, HAFEZI-RACHTI S, WONKA A, RUPPRECHT HD: ANCA-associated vasculitis with renal involvement: an outcome analysis. Nephrol Dial Transplant 2004; 19: 1403-11.
18. WESTMAN KWA, SELGA D, ISBERG P-E, BLADSTROM A, OLSSON H: High proteinase 3-anti-neutrophil cytoplasmic antibody (ANCA) level measured by the capture enzyme linked immunosorbent assay method is associated with decreased patient survival in ANCA-associated vasculitis with renal involvement. J Am Soc Nephrol 2003; 14: 2926-33.
19. BURKHARDT O, KOHNLEIN T, WRENGFR E, LUX A, NEUMANN K-H, WELTE T: Predicting outcome and survival in patients with Wegener's granulomatosis treated on the intensive care unit. Scand J Rheumatol 2007; 36: 119-24.
20. KAMALI S, INANAC M, GÜL A et al.: Systemic necrotizing vasculitides in Turkey: a comparative analysis of 40 consecutive patients. Rheumatol Int 2005; 26: 16-20.
21. GUILLEVIN L, CORDIER J-F, LHOTE F et al.: A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997; 40: 2187-98.
22. ZYCINSKA K, WARDYN KA, TYSZKO P, OTTO M: Analysis of early death based on the prediction model in Wegener's granulomatosis with pulmonary and renal involvement. J Physiol Pharmacol 2007; 58 (Suppl. 5): 829-37.
23. FILER AD, GARDNER-MEDWIN JM, THAMBYRAJAH J et al.: Diffuse endothelial dysfunction is common to ANCA associated systemic vasculitis and polarteritis nodosa. Ann Rheum Dis 2003; 62, 162-7.
24. KNIGHT A, ASKLING J, EKBOM A: Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis. Int J Cancer 2002; 100: 82-5.
25. KNIGHT A, ASKLING J, GRANATH F, SPAREN P, EKBOM A: Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide. Ann Rheum Dis 2004; 63; 1307-11.
26. FAURSCHOU M, SORENSEN IJ, MELLEMKJAER L et al.: Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 2008; 35: 100-5.
27. LUQMANI RA, BACON PA, MOOTS RJ et al.: Birmingham vasculitis activity score (BVAS) in systemic necrotizing vasculitis. Q J Med 1994; 87: 671-8.
28. GAYRAUD M, GUILLEVIN L, LE TOUMELIN, P, COHEN P, LHOTE F, CASASSUS P, JARROUSSE B and THE FRENCH VASCULITIS GROUP: Long-term follow-up of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome. Analysis of four prospective trials including 278 patients. Arthritis Rheum 2001; 44: 666-75.
29. DAVSON J, BALL J, PLATT R: The kidney in periarteritis nodosa. Q J Med 1949; 17: 175-202.
30. WATTS RA, JOLLIFFE VA, CARRUTHERS DM, LOCKWOOD M, SCOTT DGI: Effect of classification on the incidence of polyarteritis nodosa and microscopic polyangiitis. Arthritis Rheum 1996; 39: 1208-12.
31. HATTORI N, MORI K, MISU K, KOIKE H, ICHIMURA M, SOBUE G: Mortality and morbidity in peripheral neuropathy associated Churg-Strauss syndrome and microscopic polyangiitis. J Rheumatol 2002; 29: 1408-14.
32. BOURGARIT A, LE TOUMELIN P, PAGNOUX C, COHEN P, MSHR A, LE GUERN V, MOUTHON L, GUILLEVIN L and THE FRENCCH VASCULITIS STUDY GROUP: Deaths occurring during the first year after treatment onset for polyarteritis nodosa, micoscopic polyangiitis, and Churg-Strauss syndrome: a retrospective analysis of causes and factors predictive of mortality based on 595 patients. Medicine 2005; 84: 323-30.
33. JENNETTE JC, FALK RJ, ANDRASSY K et al.: Nomenclature of Systemic Vasculitides. Arthritis Rheum 1994; 37: 187-92.
34. SOLANS R, BOSCH JA, PÉREZ-BOCANEGRA C et al.: Churg-Strauss syndrome: outcome and long-term follow-up of 32 patients. Rheumatology 2001; 40: 763-71.
35. PILLEBOUT E, THERVET E, HILL G, ALBERTI C, VANHILLE P, NOCHY D: Henoch-Schönlein Purpura in adults: Outcome and prognostic factors. J Am Soc Nephrol 2002; 13: 1271-8.
36. BLANCO R, MARTINEZ-TABOADA VM, RODRIGUEZ-VALVERDE V, GARCIA-FUENTES M GONZALEZ-GAY MA: Henoch-Schönlein purpura in adulthood and childhood. Two different expressions of the same syndrome. Arthritis Rheum 1997; 40: 859-64.
37. NARCHI H: Risk of long-term renal impairment and duration of follow up recommended for Henoch-Schönlein purpura with normal or minimal urinary findings: a systematic review. Arch Dis Child 2005; 90: 916-20.
38. BUTANI L, MORGENSTERN BZ: Long-term outcome in children after Henoch-Schönlein purpura nephritis. Clin Pediatr 2007; 46: 505-11.
39. RONKAINEN J, NUUTINEN M, KOSKIMIES O: The adult kidney 24 years after childhood Henoch-Schönlein purpura: a retrospective cohort study. Lancet 2002; 360: 666-70.
40. TARSHISH, P, BERNSTEIN, J, EDELMANN, CM: Henoch-Schönlein purpura nephritis: course of disease and efficacy of cyclophosphamide. Pediatr Nephrol 2004; 19: 51-6.
41. GOLDSTEIN, AR, WHITE, RHR: Long-term follow-up of childhood Henoch-Schönlein nephritis. Lancet 1992; 339: 280-2.
42. LIGHTFOOT JR RW, MICHEL BA, BLOCH DA, HUNDER CG, ZVAIFRER NJ, MCSHANE DJ, AREND WP, CALABRESE LH, LEAVITT RY, LIE JT et al.: The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum 1990; 33: 1088-93.
43. AGARD C, MOUTHON L, MAHR A, GUIL-LEVIN L: Microscopic polyangiitis and polyarteritis nodosa: how and when do they start? Arthritis Rheum (2003); 49: 709-15.
44. GUILLEVIN L, LHOTE F, COHEN P, SAUVAGET F, JAROUSSE B, LORTHOLARY O, NOEL L-H, TREPO C: Polyarteritis nodosa re- lated to hepatitis B virus: a prospective study with long-term observation of 41 patients. Medicine (Baltimore) 1995; 74: 238-53.
45. GUILLEVIN L, LHOTE F, GAYRAUD M, COHEN P, JARROUSSE B, LORTHOLARY O, THIBULT N, CASASSUS P: Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome: a prospective study in 342 patients. Medicine (Baltimore) 1996; 75: 17-28.
46. ZIZIC TM, CLASSEN JN, STEVENS MB: Acute abdominal complications of systemic lupus erythematosus and polyarteritis nodosa. Am J Med 1982; 73: 525-31.
47. LEVINE SM, HELLMANN DB, STONE JH: Gastrointestinal involvement in polyarteritis nodosa (1986-2000): presentation and outcomes in 24 patients. Am J Med 2002; 112: 386-91.
48. KAWASAKI T: Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Clinical observation of 50 patients. Jpn J Allergol (1967); 16: 178-222.
49. YANAGAWA H, NAKAMURA Y, YASHIRO M, OKI I, HIRATA S, ZHANG T, KAWASAKI T: Incidence survey of Kawasaki Disease in 1997 and 1998 in Japan. Pediatrics 2001; 107: e33.
50. HARNDEN A, ALVES B, SHEIKH A: Rising incidence of Kawasaki disease in England: analysis of hospital admission data. BMJ 2002; 324: 1424-5.
51. BROGAN PA, BOSE A, BURGNER D, SHINGADIA D, TULLAH R, MICHIE C, KLEIN N, BOOY R, LEVIN M, DILLON MJ: Kawasaki Disease: an evidence based approach to diagnosis, treatment, and proposals for future research. Arch Dis Child 2002; 86: 286-90.
52. SINGH S, BANSAL A, GUPTA A, KUMAR RM, MITTAL BR: Kawasaki Disease. A decade of experience from North India. Int Heart J 2005; 46: 679-89.
53. DURONGPISITKUL K, GURARAJ VJ, PARK JM, MARTIN CF: The prevention of coronary artery aneurysm in Kawasaki Disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. J Pediatr 1995; 96: 1057-61.
54. LAUPLAND KB, DELE DAVIES H: Epidemiology, etiology, and management of Kawasaki Disease: State of the Art. Pediatr Cardiol 1999; 20: 177-83.
55. MCMORROW TUOHY AM, TANI LY, CETTA F, LEWIN MB, EIDEM B.W, VAN BUREN P, WILLIAMS RV, SHADDY RE, TUOHY RP, MINICH LL: How many echocardiograms are necessary for follow-up evaluation of patients with Kawasaki disease? Am J Cardiol 2001; 88: 328-30.
56. KATO H, ICHINOSE E, YOSHIOKA F, TAKECHI T, MATSUNAGA S, SUZUKI K, RIKITAKE N: Fate of coronary aneurysms in Kawasaki disease: serial coronary angiography and longterm follow-up study. Am J Cardiol 1982; 49: 1758-66.
57. KATO H, SUGIMURA T, AKAGI T, SATO N, HASHINO K, MAENO Y, KAZUE T, ETD G, YAMAKAWA R: Long-term consequences of Kawasaki Disease. A 10- to 21- year follow-up study of 594 patients. Circulation 1996; 94: 1379-85.
58. KATO H, KOIKE S, YOKOYAMA T: Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics 1979; 63: 175-9.
59. KAKU Y, NOHARA K, HONDA S: Renal involvement in Henoch-Schönlein purpura: a multivariate analysis of prognostic factors. Kidney Int 1998; 53: 1755-9.
60. NAKAMURA Y, ASO E, YASHIRO M, UEHARA R, WATANABE M, OKI I, YANAGAWA H: Mortality among persons with a history of Kawasaki disease in Japan. Circulation 2008; 72: 134-8.
61. IEMURA M, ISHII M, SUGIMURA T, AKAGI T, KATO H: Long term consequences of regressed aneurysms after Kawasaki disease: vascular wall morphology and function. Heart 2000; 83: 307-11.
62. BURNS JC, SHIKE H, GORDON JB, MALHOTRA A, SHOENWETTER M, KAWASAKI T: Sequelae of Kawasaki disease in adolescents and young adults. Am J Cardiol 1996; 28: 253-7.
63. LIE JT and THE MEMBERS AND CONSULTANTS OF THE AMERICAN COLLEGE OF RHEUMATOLOGY SUBCOMMITTEE ON CLASSIFICATION OF VASCULITIS: Illustrated histopathologic classification criteria for selected vasculitis syndromes. Arthritis Rheum 1990; 33: 1074-87.
64. SALVARANI C, CANTINI F, BOIARDI L, HUNDER CG: Polymyalgia rheumatica and giantcell arteritis. New Engl J Med 2002; 347: 261-71.
65. HUSTON KA, HUNDER CG, LIE JT, KENNEDY RH, ELVEBACK LR: Temporal arteritis: a 25-year epidemiologic, clinical, and pathologic study. Ann Intern Med 1978; 88: 162-7.
66. NORDBORG E, BENGTSSON B-A: Death rates and causes of death in 284 consecutive patients with giant cell arteritis confirmed by biopsy. BMJ 1989; 299: 549-50.
67. GRAN JT, MYKLEBUST G, WILSGAARD T, JACOBSEN BK: Survival in polymyalgia rheumatica and temporal arteritis: a study of 398 cases and matched population controls. Rheumatology 2001; 40: 1238-42.
68. MATTESON EL, GOLD KN, BLOCH DA, HUNDER GG: Long-term survival of patients with giant cell arteritis in the American College of Rheumatology giant cell arteritis classification criteria cohort. Am J Med 1996; 100: 193-6.
69. UDDHAMAR A, ERIKSSON A-L, NYSTRÖM L, STENLING R, RANTAPÄÄ-DAHLQVIST S: Increased mortality due to cardiovascular disease in patients with giant cell arteritis in Northern Sweden. J Rheumatology 2002; 29: 737-42.
70. GONZALEZ-GAY MA, RUBTERA G, PIŇEIRO A, GARCIA-PORRUA C, PEGO-REIGOSA R, GONZALEZ-JUANATEY C, SANCHEZ-ANDRADE A, LLORCA J: Ischemic heart disease in patients from Northwest Spain with biopsy proven giant cell arteritis. A population based study. J Rheumatol 2005; 32: 502-6.
71. TAKAYASU M: A case of perculiar changes of the retinal central vessels. Acta Societis Opthalmological Japonicae 1908; 12: 554-5.
72. MAKSIMOWICZ-MCKINNON K, CLARK TM, HOFFMAN GS: Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. Arthritis Rheum 2007; 1000-9.
73. RAJKUMAR C, MASON JC: Takayasu's arteritis: a cause of prolonged arterial stiffness. Rheumatology 2006; 45: 741-5.
74. SHARMA BK, JAIN S, RADOTRA BD: An autopsy study of Takayasu Arteritis in India. Int J Cardiol 1998; 66 (Suppl. 1): S85-90.
75. HOFFMAN GS, MERKEL PA, BRASINGTON RD, LENSCHOW DJ, LIANG P: Anti-tumour necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 2004; 50: 2296-304.
76. DABAGUE J, REYES P: Takayasu arteritis in Mexico: a 38-year clinical perspective through literature review. Int J Cardiol 1996; 54 (Suppl.): S87-93.
77. ISHIKAWA K, MAETANI S: Long-term outcome for 120 Japanese patients with Takayasu's Disease. Clinical and statistical analyses of related prognostic factors. Circulation 1994; 90: 1855-60.
78. JAIN S, KUMARI S, GANGULY NK, SHARMA BK: Current status of Takayasu areteritis in India. Int J Cardiol 1996; 54 (Suppl.): S111-6.
79. KERR GS, HALLAHAN CW, GIORDANA J, LEAVITT RY, FAUCI AS, ROTTEM M, HOFFMAN GS: Takayasu arteritis. Ann Intern Med 1994; 120: 919-29.
80. MWIPATAYI BP, JEFFERY PC, BENINGFIELD SJ, MATLEY PJ, NAIDOO NG KALLA AA, KAHN D: Takayasu arteritis: Clinical features and management report of 272 cases. ANZ J Surg 2005; 75: 110-7.
81. PARK M-C, LEE S-W, PARK Y-B, CHUNG NS, LEE S-K: Clinical characteristics and outcomes of Takayasu arteritis: analysis of 108 patietns using standardised criteria for diagnosis, activity, assessment, and angiographic classification. Scand J Rheumatol 2005; 34: 282-92.
82. VANOLI M, DAINA E, SALVARANI, C, SABBADINI MG, ROSSI C, BACCHIANI G, SCHIEPPATI A, BALDISSERA E, BERTOLINI G and the ITAKA STUDY GROUP: Takayasu arteritis: a study of 104 Italian patients. Arthritis Care Res 2005; 53: 100-7.
83. PARKER F, HEALEY LA, WILSKE KR, ODLAND GF: Light and electron microscopic studies on human temporal arteries with special reference to alterations related to senescence, atherosclerosis and giant cell arteritis. Am J Pathol 1975; 79: 57-80.
84. GONZALEZ-JUANATEY C, LOPEZ-DIAZ MJ, MARTIN J, LLORCA J, GONZALEZ-GAY MA: Atherosclerosis in patients with biopsy-proven giant cell arteritis. Arthritis Rheum 2007; 57: 1481-6.
85. ADU D, HOWIE AJ, SCOTT DG, BACON PA, MCGONIGLE RJ, MICHAEL J: Polyarteritis and the kidney. Q J Med 1987; 62: 221-37.
86. BIRCK R, SCHMITT WH, KAELSCH IA, VAN DER WOUDE FJ: Serial ANCA determinations for monitoring disease activity in patients with ANCA-associated vasculitis: systematic review. Am J Kidney Dis 2006; 47: 15-23.
87. NESHER G, SONNENBLICK M, FRIEDLANDER Y: Analysis of steroid related complications and mortality in temporal arteritis: a 15-year survey of 43 patients. J Rheumatol 1994; 21: 1283-6.
88. SALVARANI C, CROWSON CS, O'FALLON WM, HUNDER GG, GABRIEL SE: Reappraisal of the epidemiology of giant cell arteritis in Olmsted County, Minnesota, over a fifty-year period. Arthritis Care Res 2004; 51: 264-8.
89. SLOT MC, TERVAERT JWC, FRANSSEN CFM, STEGEMAN CA: Renal survival and prognostic factors in patients with PR3-ANCA associated vasculitis with renal involvement. Kidney Int 2003; 63: 670-7.
90. GRAHAM E, HOLLAND A, AVERY A, RUSSELL RWR: Prognosis in giant-cell arteritis. BMJ 1981; 282: 269-71.
91. HELLMICH B, KAUSCH I, DOEHN C, JOCHAM D, HOLL-ULRICH K, GROSS WL: Urinary bladder cancer in Wegener's granulomatosis: is it more than cyclophosphamide? Ann Rheum Dis 2004; 63: 1183-5.